Lipolysis in lipid turnover, cancer cachexia, and obesity-induced insulin resistance

Trends in Endocrinology and Metabolism

Volumn 25, Issue 5, 2014, Pages 255-262

  Arner, Peter ^a   Langin, Dominique ^b,c,d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b CNRS   (France)

^c UNIVERSITÉ DE TOULOUSE   (France)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Cancer cachexia; Insulin resistance; Lipolysis; Obesity; Triglyceride turnover

Indexed keywords

CACHEXIA; COMPLICATION; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LIPOLYSIS; METABOLISM; NEOPLASM; OBESITY; PHYSIOLOGY;

CACHEXIA; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; LIPOLYSIS; NEOPLASMS; OBESITY;

EID: 84899489259     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2014.03.002     Document Type: Review

References (73)

1. Ahmadian M., et al. Lipolysis in adipocytes. Int. J. Biochem. Cell Biol. 2010, 42:555-559.
2. Lafontan M., Langin D. Lipolysis and lipid mobilization in human adipose tissue. Prog. Lipid Res. 2009, 48:275-297.
3. Zechner R., et al. FAT SIGNALS - lipases and lipolysis in lipid metabolism and signaling. Cell Metab. 2012, 15:279-291.
4. Bartness T.J., et al. Sensory and sympathetic nervous system control of white adipose tissue lipolysis. Mol. Cell. Endocrinol. 2010, 318:34-43.
5. Manolopoulos K.N., et al. Marked resistance of femoral adipose tissue blood flow and lipolysis to adrenaline in vivo. Diabetologia 2012, 55:3029-3037.
6. Lafontan M., et al. Control of lipolysis by natriuretic peptides and cyclic GMP. Trends Endocrinol. Metab. 2008, 19:130-137.
7. Ahmed K., et al. An autocrine lactate loop mediates insulin-dependent inhibition of lipolysis through GPR81. Cell Metab. 2010, 11:311-319.
8. Blad C.C., et al. G protein-coupled receptors for energy metabolites as new therapeutic targets. Nat. Rev. Drug Discov. 2012, 11:603-619.
9. Sakurai T., et al. Identification of a novel GPR81-selective agonist that suppresses lipolysis in mice without cutaneous flushing. Eur. J. Pharmacol. 2014, 727C:1-7.
10. Shen H.C., Colletti S.L. Novel patent publications on high-affinity nicotinic acid receptor agonists. Expert Opin. Ther. Pat. 2009, 19:957-967.
11. Konige M., et al. Role of adipose specific lipid droplet proteins in maintaining whole body energy homeostasis. Biochim. Biophys. Acta 2014, 1842:393-401.
12. Girousse A., Langin D. Adipocyte lipases and lipid droplet-associated proteins: insight from transgenic mouse models. Int. J. Obes. (Lond.) 2012, 36:581-594.
13. Haemmerle G., et al. Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science 2006, 312:734-737.
14. Bezaire V., et al. Contribution of adipose triglyceride lipase and hormone-sensitive lipase to lipolysis in hMADS adipocytes. J. Biol. Chem. 2009, 284:18282-18291.
15. Lass A., et al. Adipose triglyceridelipase-mediated lipolysis of cellular fat stores is activated by CGI-58 and defective in Chanarin-Dorfman Syndrome. Cell Metab. 2006, 3:309-319.
16. 1 switch gene 2 regulates adipose lipolysis through association with adipose triglyceride lipase. Cell Metab. 2010, 11:194-205.
17. Ahmadian M., et al. Desnutrin/ATGL is regulated by AMPK and is required for a brown adipose phenotype. Cell Metab. 2011, 13:739-748.
18. Pagnon J., et al. Identification and functional characterization of protein kinase A phosphorylation sites in the major lipolytic protein, adipose triglyceride lipase. Endocrinology 2012, 153:4278-4289.
19. Krintel C., et al. Ser649 and Ser650 are the major determinants of protein kinase A-mediated activation of human hormone-sensitive lipase against lipid substrates. PLoS ONE 2008, 3:e3756.
20. Granneman J., et al. Perilipin controls lipolysis by regulating the interactions of AB-hydrolase containing 5 (Abhd5) and adipose triglyceride lipase (Atgl). J. Biol. Chem. 2009, 284:34538-34544.
21. 2O. Am. J. Physiol. Endocrinol. Metab. 2004, 286:E577-E588.
22. Arner P., et al. Dynamics of human adipose lipid turnover in health and metabolic disease. Nature 2011, 478:110-113.
23. Arner P. Is familial combined hyperlipidaemia a genetic disorder of adipose tissue?. Curr. Opin. Lipidol. 1997, 8:89-94.
24. Ryden M., et al. Adipocyte triglyceride turnover and lipolysis in lean and overweight subjects. J. Lipid Res. 2013, 54:2909-2913.
25. Frayn K., et al. Adipocyte triglyceride turnover is independently associated with atherogenic dyslipidemia. J. Am. Heart Assoc. 2012, 1:e003467.
26. Bluher M. The distinction of metabolically 'healthy' from 'unhealthy' obese individuals. Curr. Opin. Lipidol. 2010, 21:38-43.
27. Bluher M. Are there still healthy obese patients?. Curr. Opin. Endocrinol. Diabetes Obes. 2012, 19:341-346.
28. Tisdale M.J. Molecular pathways leading to cancer cachexia. Physiology (Bethesda) 2005, 20:340-348.
29. Bing C., Trayhurn P. Regulation of adipose tissue metabolism in cancer cachexia. Curr. Opin. Clin. Nutr. Metab. Care 2008, 11:201-207.
30. Agustsson T., et al. Mechanism of increased lipolysis in cancer cachexia. Cancer Res. 2007, 67:5531-5537.
31. Das S.K., et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science 2011, 333:233-238.
32. Cao D.X., et al. Role of beta1-adrenoceptor in increased lipolysis in cancer cachexia. Cancer Sci. 2010, 101:1639-1645.
33. Laurencikiene J., et al. Evidence for an important role of CIDEA in human cancer cachexia. Cancer Res. 2008, 68:9247-9254.
34. Ryden M., et al. Lipolysis - not inflammation, cell death, or lipogenesis - is involved in adipose tissue loss in cancer cachexia. Cancer 2008, 113:1695-1704.
35. Guilherme A., et al. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat. Rev. Mol. Cell Biol. 2008, 9:367-377.
36. Nordstrom E.A., et al. A human-specific role of cell death-inducing DFFA (DNA fragmentation factor-alpha)-like effector A (CIDEA) in adipocyte lipolysis and obesity. Diabetes 2005, 54:1726-1734.
37. Puri V., et al. Cidea is associated with lipid droplets and insulin sensitivity in humans. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:7833-7838.
38. Mracek T., et al. Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients. Br. J. Cancer 2011, 104:441-447.
39. Ryden M., et al. Adipose zinc-alpha2-glycoprotein is a catabolic marker in cancer and noncancerous states. J. Intern. Med. 2012, 271:414-420.
40. Bing C. Lipid mobilization in cachexia: mechanisms and mediators. Curr. Opin. Support. Palliat. Care 2011, 5:356-360.
41. Claus T.H., et al. Specific inhibition of hormone-sensitive lipase improves lipid profile while reducing plasma glucose. J. Pharmacol. Exp. Ther. 2005, 315:1396-1402.
42. Ebdrup S., et al. Synthesis and structure-activity relationship for a novel class of potent and selective carbamate-based inhibitors of hormone selective lipase with acute in vivo antilipolytic effects. J. Med. Chem. 2007, 50:5449-5456.
43. Wang M., Fotsch C. Small-molecule compounds that modulate lipolysis in adipose tissue: targeting strategies and molecular classes. Chem. Biol. 2006, 13:1019-1027.
44. Mayer N., et al. Development of small-molecule inhibitors targeting adipose triglyceride lipase. Nat. Chem. Biol. 2013, 9:785-787.
45. Arner P. Human fat cell lipolysis: biochemistry, regulation and clinical role. Best Pract. Res. Clin. Endocrinol. Metab. 2005, 19:471-482.
46. Langin D., et al. Adipocyte lipases and defect of lipolysis in human obesity. Diabetes 2005, 54:3190-3197.
47. Moro C., Lafontan M. Natriuretic peptides and cGMP signaling control of energy homeostasis. Am. J. Physiol. Heart Circ. Physiol. 2013, 304:H358-H368.
48. Blaak E. Gender differences in fat metabolism. Curr. Opin. Clin. Nutr. Metab. Care 2001, 4:499-502.
49. Langin D., Arner P. Importance of TNFalpha and neutral lipases in human adipose tissue lipolysis. Trends Endocrinol. Metab. 2006, 17:314-320.
50. Ryden M., Arner P. Tumour necrosis factor-alpha in human adipose tissue - from signalling mechanisms to clinical implications. J. Intern. Med. 2007, 262:431-438.
51. Gustafson B., et al. Inflammation and impaired adipogenesis in hypertrophic obesity in man. Am. J. Physiol. Endocrinol. Metab. 2009, 297:E999-E1003.
52. Fain J.N., et al. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004, 145:2273-2282.
53. Chen X., et al. TNF-alpha, a potent lipid metabolism regulator. Cell Biochem. Funct. 2009, 27:407-416.
54. Yang X., et al. Relative contribution of adipose triglyceride lipase and hormone-sensitive lipase to tumor necrosis factor-alpha (TNF-alpha)-induced lipolysis in adipocytes. J. Biol. Chem. 2011, 286:40477-40485.
55. Jager J., et al. Tpl2 kinase is upregulated in adipose tissue in obesity and may mediate interleukin-1beta and tumor necrosis factor-alpha effects on extracellular signal-regulated kinase activation and lipolysis. Diabetes 2010, 59:61-70.
56. Lee M.J., Fried S.K. Glucocorticoids antagonize tumor necrosis factor-alpha-stimulated lipolysis and resistance to the antilipolytic effect of insulin in human adipocytes. Am. J. Physiol. Endocrinol. Metab. 2012, 303:E1126-E1133.
57. Deng J., et al. Lipolysis response to endoplasmic reticulum stress in adipose cells. J. Biol. Chem. 2012, 287:6240-6249.
58. Trayhurn P. Hypoxia and adipose tissue function and dysfunction in obesity. Physiol. Rev. 2013, 93:1-21.
59. Goossens G.H., et al. Increased adipose tissue oxygen tension in obese compared with lean men is accompanied by insulin resistance, impaired adipose tissue capillarization, and inflammation. Circulation 2011, 124:67-76.
60. Hodson L., et al. Metabolic signatures of human adipose tissue hypoxia in obesity. Diabetes 2013, 62:1417-1425.
61. McLaughlin T., et al. Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity. Arch. Int. Med. 2007, 167:642-648.
62. Boden G. Obesity, insulin resistance and free fatty acids. Curr. Opin. Endocrinol. Diabetes Obes. 2011, 18:139-143.
63. Karpe F., et al. Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes 2011, 60:2441-2449.
64. Girousse A., et al. Partial inhibition of adipose tissue lipolysis improves glucose metabolism and insulin sensitivity without alteration of fat mass. PLoS Biol. 2013, 11:e1001485.
65. Cinti S., et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J. Lipid Res. 2005, 46:2347-2355.
66. Harada K., et al. Resistance to high-fat diet-induced obesity and altered expression of adipose-specific genes in HSL-deficient mice. Am. J. Physiol. Endocrinol. Metab. 2003, 285:E1182-E1195.
67. Hoy A.J., et al. Adipose triglyceride lipase-null mice are resistant to high-fat diet-induced insulin resistance despite reduced energy expenditure and ectopic lipid accumulation. Endocrinology 2011, 152:48-58.
68. Kienesberger P.C., et al. Adipose triglyceride lipase deficiency causes tissue-specific changes in insulin signaling. J. Biol. Chem. 2009, 284:30218-30229.
69. Radner F.P., et al. Growth retardation, impaired triacylglycerol catabolism, hepatic steatosis, and lethal skin barrier defect in mice lacking comparative gene identification-58 (CGI-58). J. Biol. Chem. 2010, 285:7300-7311.
70. Zhang X., et al. Targeted disruption of the G0/G1 switch gene 2 enhances adipose lipolysis, alters hepatic energy balance, and alleviates high-fat diet-induced liver steatosis. Diabetes 2014, 63:934-946.
71. Herman M.A., et al. A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism. Nature 2012, 484:333-338.
72. Roberts R., et al. Markers of de novo lipogenesis in adipose tissue: associations with small adipocytes and insulin sensitivity in humans. Diabetologia 2009, 52:882-890.
73. Sedwick C. Breaking down insulin resistance. PLoS Biol. 2013, 11:e1001483.